This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Erlichman, C. Articles by Chabner, B. A. Search for Related Content PubMed PubMed Citation Articles by Erlichman, C. Articles by Chabner, B. A.

Phase I Trial of N-(Phosphonacetyl)-L-aspartate

Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205

A Phase I clinical trial of N-(phosphonacetyl)-L-aspartate, an antimetabolite which inhibits a key enzyme in the de novo pathway of pyrimidine biosynthesis, was conducted. N-(Phosphonacetyl)-L-aspartate was given as an i.v. 15-min infusion once daily for five days; cycles of treatment were repeated every three weeks. Thirty-four patients received treatment. Dose-limiting toxicity was observed at 1500 to 2000 mg/sq m/day and was manifested by skin rash, diarrhea, and stomatitis. Rash and diarrhea usually began during the first week of treatment and persisted up to Day 17 of a cycle of therapy. No consistent hematopoietic, hepatic, or renal toxicity was observed. One partial response in a patient with colon carcinoma was seen and continues at more than eight months. Stable disease was observed in three patients with colon carcinoma, two patients with hypernephroma, one patient with pancreatic carcinoma, and one patient with melanoma. The predictability and reversibility of toxicity and the suggestion of antitumor activity in humans are observations which support the further evaluation of N-(phosphonacetyl)-L-aspartate in Phase II studies.

¹ Fellow of the Medical Research Council of Canada.

² To whom requests for reprints should be addressed, at Building 10, Room 6N119, National Cancer Institute, NIH, Bethesda, Md. 20205.

Received 4/25/79. Accepted 7/10/79.